A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Solid Tumours
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 540 (planned)
- Started
- Oct 15, 2025
- Main results expected
- Jul 31, 2028
- Fully finished
- Aug 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AE)
Measured over: Up to approximately 2 years
Number of Participants with Serious Adverse Events (SAE)
Measured over: Up to approximately 2 years
Number of Participants with AEs meeting protocol-defined Dose-limiting Toxicities (DLTs) criteria
Measured over: Up to Day 21
Number of Participants with AEs Leading to Discontinuation
Measured over: Up to approximately 2 years
Number of Participants with AEs Leading to Deaths
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07160725 · record last updated 2026-08-11 · checked 2026-11-09 15:47 UTC